April 23, 2018
Authored and Edited by Paula E. Miller; Shana K. Cyr, Ph.D.
On April 18, 2018, FDA issued draft guidance on Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products—Quality Considerations. The guidance explains the chemistry, manufacturing, and controls (CMC) information that applicants should include in NDAs and ANDAs. The guidance updates and replaces the draft guidance from November 13, 1998.
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) are drug-device combination products consisting of at least one drug substance and a container closure system. The drug is delivered via inhalation to treat respiratory diseases.
The guidance provides recommendations on critical quality attributes (CQAs) to be developed, and how those attributes relate to elements of the desired quality target product profile (QTPP). The QTPP includes the characteristics that ideally will be achieved to ensure the desired quality; for MDIs and DPIs, these elements include proposed dosage form and delivery system, strength (e.g., targeted metered dose for DPIs, targeted delivered dose for MDIs), purity, stability, and aerodynamic performance. FDA indicates that potential product CQAs for MDIs and DPIs typically comprise assay, impurities and degradants, delivered dose, aerodynamic particle size distribution, foreign particulate matter, moisture content, net content (drug substance and excipients), microbial load, and device constituent part characteristics. The guidance contains additional CQAs specific to the drug substance, excipients, and container closure systems for MDIs and DPIs.
FDA recommends considering factors during product and process development that may impact product quality, including common design and development issues and typical manufacturing operation issues. The guidance also outlines the development of a control strategy to ensure that the CQAs are within the appropriate range, limit, or distribution to assure drug substance and product quality.
The guidance identifies technical data and information that should be submitted in NDAs and ANDAs, following the format of the ICH M4Q and focusing on aspects of MDIs and DPIs that are unique to these products. For example, FDA recommends that the section on pharmaceutical development address the development process for the entire product, including the device constituent part, because an MDI or DPI is a combination product. The guidance also gives recommendations for labelling to help achieve consistency, including naming conventions, information to include on the container/carton label, as well as specifics for sections of the prescribing information such as the description, storage and handling, and instructions for use.
Readers are encouraged to read the draft guidance. Comments and suggestions regarding the draft guidance should be submitted to FDA by June 18, 2018.
combination product, drugs, FDA Guidance, Food and Drug Administration (FDA), new drug application (NDA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
May 9, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.